Literature DB >> 14629466

Knowledge and educational needs of individuals with the factor V Leiden mutation.

E A Hellmann1, N D Leslie, S Moll.   

Abstract

BACKGROUND: Genetic testing for factor (F)V Leiden is widely performed in an effort to prevent thrombosis-related morbidity. The implications of a positive test for patients' health perception and the extent of patients' understanding of results are not known.
OBJECTIVES: This study examined patient experience of genetic testing for FV Leiden. PATIENTS AND METHODS: The study was a cross-sectional, mailed survey of 110 patients who tested positive for the FV Leiden gene mutation at an academic medical center between 1995 and 2001. Patient knowledge about FV Leiden, satisfaction with available information, and psychosocial reactions to testing were assessed and the influence of demographic and clinical characteristics on outcome measured.
RESULTS: The magnitude of thrombosis risk associated with FV Leiden was incorrectly estimated by 79% of participants. Many patients (64%) stated that they had not been given much information about FV Leiden and 68% still had many questions. Most patients (53%) felt that their healthcare providers do not understand FV Leiden. Patients who had been seen by a hematologist or in a specialized thrombosis clinic were more knowledgeable and had less information need. Most patients (88%) were glad to know genetic test results, despite negative psychosocial implications such as increased worry (43%).
CONCLUSIONS: Knowledge of genetic status increases awareness of thrombosis risk among patients, but magnitude of risk is often overestimated. Affected individuals indicate that there is a lack of available information about FV Leiden and that additional educational resources are needed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14629466     DOI: 10.1046/j.1538-7836.2003.00448.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  13 in total

1.  The U.S. Thrombosis and Hemostasis Centers pilot sites program.

Authors:  N F Dowling; M G Beckman; M Manco-Johnson; K Hassell; C S Philipp; L A Michaels; S Moll; J A Heit; J Penner; R Kulkarni; S Pipe; P Bockenstedt; J Andersen; S Crudder; A H James; S Zimmerman; T L Ortel
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

Review 2.  Issues concerning the laboratory investigation of inherited thrombophilia.

Authors:  Armando Tripodi
Journal:  Mol Diagn       Date:  2005

Review 3.  Role of thrombophilia testing: con.

Authors:  Scott M Stevens
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 4.  Testing for thrombophilia: an evidence-based approach.

Authors:  L Merriman; M Greaves
Journal:  Postgrad Med J       Date:  2006-11       Impact factor: 2.401

5.  Cognitive and behavioural effects of genetic testing for thrombophilia.

Authors:  J Heshka; C Palleschi; B Wilson; J Brehaut; J Rutberg; H Etchegary; N Langlois; M Rodger; P S Wells
Journal:  J Genet Couns       Date:  2008-02-21       Impact factor: 2.537

Review 6.  Genetic counseling for inherited thrombophilias.

Authors:  Elizabeth A Varga
Journal:  J Thromb Thrombolysis       Date:  2007-10-19       Impact factor: 2.300

7.  Patient compliance based on genetic medicine: a literature review.

Authors:  Kai Insa Schneider; Jörg Schmidtke
Journal:  J Community Genet       Date:  2013-08-10

Review 8.  Thrombophilias--practical implications and testing caveats.

Authors:  Stephan Moll
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

Review 9.  Inherited thrombophilia: key points for genetic counseling.

Authors:  Elizabeth Varga
Journal:  J Genet Couns       Date:  2007-05-01       Impact factor: 2.717

10.  Patients' understanding of genetic susceptibility testing in mainstream medicine: qualitative study on thrombophilia.

Authors:  Paula M Saukko; Sian Ellard; Suzanne H Richards; Maggie H Shepherd; John L Campbell
Journal:  BMC Health Serv Res       Date:  2007-06-12       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.